关键词: 肺癌, T淋巴细胞, 自然杀伤细胞, 生命质量

Abstract:

 Objective： To investigate the changes and correlations of peripheral blood T lymphocyte subsets， natural killer cells （NK） and quality of life scores in patients with advanced lung cancer before and after antitumour therapy.Methods： A prospective study was conducted on 70 patients with advanced lung cancer who received treatment at our hospital's oncology department from January 2022 to July 2024. Repeated measures analysis of variance was employed to analyze changes in clinicopathological data， peripheral blood T lymphocyte subsets， NK cells， and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 （EORTC QLQ-C30） scores before treatment， at 3 months post-treatment， and at 6 months post-treatment. Simple linear correlation analysis was used to examine the relationship between laboratory indicators and EORTC QLQ-C30 scores.Results： Patients aged <60 years exhibited significantly higher total quality of life scores compared to those ≥60 years （P<0.05）. Patients with TNM stage III inoperable disease demonstrated higher functional domain and total quality of life scores than stage IV patients， while showing lower symptom domain scores （P<0.05）. Patients with pleural effusion had lower functional domain and total quality of life scores but higher symptom domain scores compared to those without pleural effusion （P<0.05）. Patients with fewer than 2 comorbidities showed higher total quality of life scores and lower symptom domain scores than those with 2 or more comorbidities （P<0.05）.Six months post-treatment， patients with advanced lung cancer exhibited significant increases in CD3⁺ （61.10±6.68）%， CD4⁺ （33.28±5.58）%， CD4⁺/CD8⁺ ratio （1.20±0.24）， NK cells （18.57±3.58）%， functional domain score （65.39±9.14）， and overall quality of life score （51.33±10.20） compared to pre-treatment levels （P<0.05）. CD8⁺ （27.67±4.52）% and symptom domain score （30.35±6.29） showed significant decreases （P<0.05）. Positive correlations were observed between CD3⁺， CD4⁺， CD4⁺/CD8⁺ ratio， NK cells and both functional domain and overall quality of life scores （P<0.05）， while negative correlations were found with the symptom domain score （P<0.05）.Conclusion： The findings indicate that post-treatment improvements in immune function and quality of life are significantly associated with functional status， symptom severity， and overall quality of life in patients with advanced lung cancer.

Key words:  , Lung cancer； , T lymphocytes； , Natural killer cells； , Quality of life